Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530500 | 0.84 | GRIA2 (0.44) | GRIA2CA1CA2SRD5A1CA12 | |
| SCHEMBL7899654 | 0.83 | GRIA2 (0.49) | GRIA2CA1CA2CA12CA7 | |
| SCHEMBL1591092 | 0.80 | GRIA2 (0.62) | GRIA2CA1CA2CA12CA7 | |
| SCHEMBL12723666 | 0.80 | GRIA2 (0.47) | GRIA2GRIA4CA1CA2SRD5A1 | |
| SCHEMBL1590737 | 0.80 | GRIA2 (0.54) | GRIA2CA1CA2CA12CA7 | |
| SCHEMBL1591240 | 0.78 | GRIA2 (0.46) | GRIA2CA1CA2CA12CA7 | |
| SCHEMBL24437313 | 0.77 | PDE4A (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30985365 | 0.77 | PDE4A (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8246017 | 0.76 | SRD5A1 (0.42) | CA1CA2SRD5A1CA12CA7 | |
| SCHEMBL31137445 | 0.76 | PDPK1 (0.58) | CA1CA2SRD5A1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297110-B1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | MERCK SHARP & DOHME (NL) | 2015-05-20 | — | — | EP | disclosed |
| EP-2297110-B1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | MERCK SHARP & DOHME (NL) | 2015-05-20 | — | — | EP | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8536214-B2 | Indane derivatives as AMPA receptor modulators | N.V. ORGANON (NL) | 2013-09-17 | — | — | US | disclosed |
| US-8536214-B2 | Indane derivatives as AMPA receptor modulators | N.V. ORGANON (NL) | 2013-09-17 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| CN-102365265-A | Indane derivatives | ORGANON NV | 2012-02-29 | — | — | CN | disclosed |
| EP-2417101-A1 | INDANE DERIVATIVES | MSD Oss B.V. (NL) | 2012-02-15 | — | — | EP | disclosed |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2011-04-21 | — | — | US | disclosed |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2011-04-21 | — | — | US | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009147167-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | GRIA2 24/4885GRIA4 45/4885CA1 924/4885 |
| US-20110092539-A1 | INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN3A, GRIK2 | GRIA2 27/4885GRIA4 33/4885CA1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.